Hormone Replacement Therapy and COVID-19 Outcomes in Solid Organ Transplant Recipients Compared With the General Population
April 2023
in “
American Journal of Transplantation
”
TLDR Hormone replacement therapy may lower the risk of severe COVID-19 outcomes in non-immunosuppressed people and male organ transplant recipients.
The study involved 1135 solid organ transplant recipients (SOTRs) and 43,383 non-immunosuppressed/immunosuppressed (non-ISC) patients on hormone replacement therapy (HRT) with COVID-19. It found that HRT use was associated with a lower risk of major adverse renal or cardiac events and all secondary outcomes in non-ISC individuals. In SOTRs, HRT reduced the risk of acute kidney injury and mortality in males with COVID-19 but not in females. The study suggests that the benefits of HRT are likely mediated through an immune pathway that is inhibited in immunosuppressed transplant recipients. However, the potentially modifying effects of immunosuppression on the benefits of HRT require further investigation.